Adam Wlodarczyk
Overview
Explore the profile of Adam Wlodarczyk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chrusciel E, Slusarczyk L, Gladyszewska B, Karcz D, Luchowski R, Nucia A, et al.
Molecules
. 2025 Feb;
30(3).
PMID: 39942635
There is currently a growing interest in imino derivatives of compounds such as thiadiazoles and other groups of compounds whose extended π-electron systems enhance their photophysical properties. These compounds also...
2.
Slupski J, Wlodarczyk A, Gorska N, Szarmach J, Slupska A, Pilecka K, et al.
Magnes Res
. 2025 Jan;
37(3):40-48.
PMID: 39846975
Impulsive behaviours affect patients with major depressive disorder (MDD) and bipolar disorder (BP), increasing suicide risk and mood instability. Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, has been reported to promote...
3.
Mechlinska A, Wlodarczyk A
Prog Neuropsychopharmacol Biol Psychiatry
. 2025 Jan;
136():111246.
PMID: 39746436
No abstract available.
4.
Kwasny A, Cubala W, Wlodarczyk A, Pastuszak K
Pharmacol Rep
. 2024 Aug;
76(6):1325-1332.
PMID: 39207673
Background: This study examines self-reported sleep alterations in treatment-resistant depression (TRD) inpatients following intravenous ketamine administration. Methods: This is a post-hoc analysis of a naturalistic observational study, which enrolled 28...
5.
Grzegorzewska A, Wiglusz M, Jakuszkowiak-Wojten K, Cubala W, Wlodarczyk A, Szarmach J
Psychiatry Clin Psychopharmacol
. 2024 Aug;
34(2):191-196.
PMID: 39165892
Patients with epilepsy present a variety of psychiatric comorbidities, with mood disorders and anxiety disorders as well as interictal dysphoric disorder as the most frequent and often associated with comorbid...
6.
Kwasny A, Kwasna J, Wilkowska A, Szarmach J, Slupski J, Wlodarczyk A, et al.
Eur Neuropsychopharmacol
. 2024 Jun;
86:20-34.
PMID: 38917771
Ketamine, an N-methyl-D-aspartate receptor antagonist, is a racemic mixture of esketamine and arketamine used to treat unipolar and bipolar depression. Preliminary reports indicate that it may be beneficial for depressed...
7.
Wlodarczyk A, Slupski J, Szarmach J, Cubala W
Asian J Psychiatr
. 2024 Mar;
96:104016.
PMID: 38554563
Background: Ketamine is the prototypal rapid-acting antidepressant (RAAD) for TRD with approved indication for esketamine-nasal spray (ESK-NS). Distinctly, arketamine (R-KET) demonstrates enhanced antidepressant effects and neuroplasticity changes compared to esketamine,...
8.
Kwasny A, Cubala W, Wlodarczyk A
Front Psychiatry
. 2024 Mar;
15:1334293.
PMID: 38439794
Background: Anhedonia is a core symptom of depression characterized by a diminished ability to experience pleasure. Currently available treatments for depression often fall short in adequately addressing anhedonia that often...
9.
Mechlinska A, Wiglusz M, Slupski J, Wlodarczyk A, Cubala W
Brain Sci
. 2023 Sep;
13(9).
PMID: 37759862
Major depressive disorder and bipolar disorder are the leading causes of global disability. Approximately 50% of patients fail to attain remission, prompting a pronounced focus on the significance of dietary...
10.
Kwasny A, Wlodarczyk A, Dywel A, Szarmach J, Strandberg O, Cubala W
Front Psychiatry
. 2023 Jul;
14:1190415.
PMID: 37398584
Introduction: The ultimate goal in major depressive disorder (MDD) treatment is recovery. A proportion of MDD patients with formal remission experience persistent difficulties, which impair their daily functioning. Residual insomnia...